Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases. Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people. We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases. Work is ongoing to develop and deepen the pipeline and realise the potential for alicaforsen to address the unmet needs of multiple patient groups. We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI motility disorders.